《大行報告》裏昂升新秀麗(01910.HK)評級至「買入」 目標價上調至22元
裏昂發表報告表示,新秀麗(01910.HK)去年扭虧錄經調整盈利1,740萬美元,遠勝市場預期,主因集團毛利率持續改善,並降低固定的銷售、一般及行政開支費用,公司並預料即使受新冠疫情及政治局勢影響,今年首季銷售會繼續收窄自2019年來的跌幅。
該行將其在2022年至23年的銷售額上調1%至6%,加上因全球逐步重開,有利於公司的中期復甦速度,故該行繼續保持樂觀態度。
裏昂將新秀麗2022年至23年純利預測調整爲1.5億美元及2.5億美元,將目標價由15.2元上調至22元,且將其評級由「跑贏大市」升至「買入」。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.